Shares of Oxford, U.K.-based Summit Therapeutics plc (NASDAQ:SMMT) rose 12.9 percent to close at $13.78 Thursday on interim data showing that its Duchenne muscular dystrophy (DMD) candidate, ezutromid, appears to have helped reduce muscle fiber damage and increased levels of a protein called utrophin, seen to offer benefits in restoring and maintaining healthy muscle function.